Agreement facilitates flexible, scalable automated industrialized production of rese-cel for many thousands of patients per year at a cost per ...

The company was studying its therapy called rese-cel at the lowest dose without preconditioning in patients with pemphigus vulgaris. ・After discontinuing all immunomodulators, two of the four patients ...

Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Cabaletta Bio (CABA) drew fresh attention from investors after announcing encouraging clinical trial results for rese-cel in several autoimmune diseases. Presentations at the American College of ...

Cabaletta Bio shares rose after the company said it is pricing an underwritten offering of about 51.7 million shares at $2.90 a share. Shares of the biotechnology company developing treatments for ...

Additional information, including the accepted abstracts, can be accessed on the website of the ASGCT 2026 Annual Meeting. Presentation materials will be made available on the Posters & Publications ...

Cabaletta didn't have any major announcements or any Securities and Exchange Commission (SEC) filings to make the stock rise. However, Guggenheim initiated coverage of the stock, with a price target ...

– Nine patients enrolled as of August 5, 2024 across the RESET™ clinical development program, including four since EULAR in June, with 22 U.S. clinical sites now enrolling – – Additional clinical data ...

– Registrational cohort enrollment in RESET-Myositis™ trial on track to start in 2H25 with anticipated 2027 BLA submission for rese-cel in myositis – – Five disease-specific cohorts fully enrolled in ...

Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced it has entered into a ...